Compare COOK & CRBU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | COOK | CRBU |
|---|---|---|
| Founded | 1985 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Wholesale Distributors | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 184.8M | 203.9M |
| IPO Year | 2021 | 2021 |
| Metric | COOK | CRBU |
|---|---|---|
| Price | $0.91 | $1.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 3 |
| Target Price | $2.04 | ★ $9.33 |
| AVG Volume (30 Days) | 675.8K | ★ 1.1M |
| Earning Date | 11-05-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $582,799,000.00 | $9,295,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $4.96 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.71 | $0.66 |
| 52 Week High | $3.31 | $3.54 |
| Indicator | COOK | CRBU |
|---|---|---|
| Relative Strength Index (RSI) | 53.62 | 43.28 |
| Support Level | $0.71 | $1.75 |
| Resistance Level | $0.84 | $1.96 |
| Average True Range (ATR) | 0.09 | 0.11 |
| MACD | 0.01 | 0.02 |
| Stochastic Oscillator | 60.08 | 60.02 |
Traeger Inc designs, sources, sells, and supports wood pellet fueled barbeque grills sold to retailers, distributors, and direct to consumers. It produces and sells the pellets used to fire the grills and also sells Traeger-branded rubs, spices, and sauces, as well as grilling accessories including covers, barbeque tools, trays, liners, and merchandise. The company's geographical segments include North America and the Rest of the world, of which majority of revenue is from North America.
Caribou Biosciences Inc is a clinical-stage Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) biopharmaceutical company dedicated to transforming the lives of patients with devastating diseases by applying its novel CRISPR platform, CRISPR hybrid RNA-DNA (chRDNA), toward the development of next-generation, genome-edited cell therapies. The company operates and manage business as one reportable operating segment, which is the business of developing a pipeline of allogeneic CAR-T and CAR-NK cell therapies. Geographically, it operates in United States and Rest of the World, of which United States derives maximum revenue.